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Abstract 30 
There is evidence that processing techniques like hot-melt extrusion (HME) could alter the 31 
mechanical properties of pharmaceuticals, which may impede further processability (e.g. 32 
tableting). The purpose of this study was to evaluate if HME has an impact on the tableting 33 
behavior of polyvinyl alcohol (PVA) – formulations. Mixtures of partially hydrolysed PVA grades 34 
(with a hydroxylation degree of 75 and 88%) and sorbitol (0, 10 and 40%) were extruded, (cryo-) 35 
milled and compressed into compacts of 350±10 mg. Before compression all intermediate 36 
products were characterized for their solid-state (Tg, Tm, crystallinity) and material properties 37 
(particle size, moisture content, moisture sorption). Because both PVA-grades required higher 38 
extrusion temperatures (>180 °C), sorbitol was added to PVA as plasticizing agent to allow 39 
extrusion at 140°C. Compaction experiments were performed on both physical mixtures and 40 
cryo-milled extrudates of PVA-sorbitol. By measuring tablet tensile strength and porosity in 41 
function of compaction pressure, tableting behavior was compared before and after HME by 42 
means of the CTC-profiles (compressibility, tabletability, compactibility). A higher amorphous 43 
content in the formulation (as a result of HME) negatively influenced the tableting behavior (i.e. 44 
lower tablet tensile strength). HME altered the mechanical properties towards more elastically 45 
deforming materials, thereby increasing tablet elastic recovery during decompression. The 46 
lower tensile strengths resulted from a combined effect of less interparticulate bonding areas 47 
(because of higher elastic recovery) and weaker bonding strengths per unit bonding area 48 
(between glassy particles).     49 
     50 
 51 
Keywords: hot-melt extrusion, tableting, elastic recovery, polyvinyl alcohol, oral drug delivery, 52 
immediate release.   53 
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1. INTRODUCTION 54 
 55 
Due to the application of high-throughput screening and medicinal chemistry as drug selection 56 
procedures, there has been a significant increase in the number of new chemical entities (NCE) 57 
that are poorly water-soluble. Pharmaceutical research, shifted their focus to new 58 
formulation strategies, in order to overcome solubility-related problems, for which the 59 
formulation of solid dispersions was a viable technique to improve the (oral) 60 
bioavailability of poorly water-soluble drug compounds (Janssens and Van den Mooter, 61 
2009; Leuner and Dressman, 2000). Different approaches are reported in order to 62 
(molecularly) disperse the active pharmaceutical ingredient (API) in its carrier (Moneghini et 63 
al., 2001; Paudel et al., 2013; Sethia and Squillante, 2004), whereby hot-melt extrusion (HME) 64 
has the advantage of being a continuous manufacturing process that is generally applicable 65 
on industrial scale, without the requirement of further drying steps (Breitenbach, 2002).  66 
Partially hydrolysed polyvinyl alcohols (PVA) were successfully screened as carriers in 67 
HME for immediate release applications, whereby PVA-grades with high degree of 68 
hydrolysis (70 – 90%) were most promising, as drug release was independent of pH (1-69 
9) and ionic strength (0 – 0.14M) (De Jaeghere et al., 2015). However, PVA-grades with 70 
high degree of hydrolysis (> 70%) have a rather high melting point onset (150-170°C), 71 
indicating that higher extrusion temperatures are needed in order to extrude these 72 
polymers, which impedes the use of thermosensitive API. De Jaeghere et al. evaluated 73 
sorbitol as plasticizer for PVA and noticed a sufficient decrease in process temperature, 74 
which could extend the application of PVA as carrier in HME (De Jaeghere et al., 2015). 75 
Various downstream processes for HME are available, from injection molding (i.e. finale 76 
dosage form) to milling of the extrudates (i.e. intermediate products) for further 77 
processability (e.g. tablets) (Treffer et al., 2013). Tablets are still the most popular dosage 78 
forms for the pharmaceutical industry and patient since they allow high-precision dosing, 79 
ensure patient compliance and provide high manufacturing efficiency. Therefore, previous 80 
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research was extended to investigate the processability of PVA and PVA-sorbitol 81 
carriers after HME into conventional tablets. The impact of solid dispersion 82 
manufacturing techniques such as HME on the tableting behaviour of pharmaceutical 83 
polymers whether or not with plasticizer, was only limited investigated (Agrawal et al., 84 
2013; Boersen et al., 2013; Dinunzio et al., 2012; Mohammed et al., 2012) with minimal 85 
focus on the mechanical properties of the pure components. These properties are of great 86 
importance in solid dosage form development and manufacturing, as they describe the 87 
behaviour of a material subjected to an applied stress (Iyer et al., 2013). In this study, PVA 88 
and physical mixtures of PVA-sorbitol were processed by HME, characterized, milled to 89 
powders of appropriate particle size and eventually processed into tablets. CTC-profiles 90 
(compressibility, tabletability, compactibility) of those tablets were drafted and compared with 91 
the physical mixtures in order to evaluate the impact of different processing steps on the 92 
mechanical properties of these materials. Axial recoveries of the tablets were calculated and 93 
linked to the CTC-profiles.  94 
  95 
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2. MATERIALS AND METHODS 96 
2.1. Materials   97 
Two types of polyvinyl alcohol (PVA) were used, a technical grade PVA505 (72-75 % hydrolysed) 98 
obtained from Kuraray (Hattersheim am Main, Germany) and a pharmaceutical grade PVA4-88 99 
(88% hydrolysed) obtained from Merck (Darmstadt, Germany). Sorbitol (Fagron, Waregem, 100 
Belgium) was used as water-soluble plasticizer and celecoxib (CEL) (Sanico, Turnhout, 101 
Belgium) was used as model drug. 102 
 103 
2.2. Hot-Melt Extrusion (HME)   104 
Physical mixtures of PVA and sorbitol (0, 10, 40 %) were processed with a co-rotating, fully 105 
intermeshing twin-screw extruder (Prism Eurolab 16, Thermo Fisher, Germany) operating at a 106 
screw-speed of 100 rpm and a process temperature of 180 °C across the entire barrel. The 107 
extruder was equipped with a gravimetric feeder (0.300 kg/h), two co-rotating twin-screws 108 
with 3 mixing zones and a cylindrical die of 3 mm. The extrudates were quench-cooled with 109 
liquid nitrogen, (cryo)-milled and sieved through a 300-micron sieve (De Jaeghere et al., 2015).  110 
 111 
2.3. Tableting  112 
Tablets (350 ± 10 mg) of physical mixtures and cryo-milled extrudates of PVA-sorbitol were 113 
prepared using a rotary tablet press (MODULTM P, GEA Pharma Systems, CourtoyTM, Halle, 114 
Belgium) equipped with a round concave (radius: 24mm) Euro B punch of 12 mm diameter at 115 
a tableting speed of 5 rpm. The compaction pressure ranged from 100 to 400 MPa after a pre-116 
compression at 17 MPa. Tablets used for thermal analysis were compacted at 305 MPa, after 117 
pre-compression at 17 MPa. All tablets were immediately after compression characterized for 118 
tablet strength, dimensions and mass.  119 
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2.4. Characterization  120 
2.4.1. Thermal analysis 121 
Differential scanning calorimetry (DSC) was performed before and after sample manipulation 122 
(HME, cryo-milling, tableting), whereby melting temperature (Tm), glass transition temperature 123 
(Tg), crystallization temperature (Tc) and heat of fusion (ΔHf) was analysed with a Q2000 DSC 124 
(TA Instruments, Leatherhead, UK) equipped with a refrigerated cooling system (RCS). The 125 
DSC cell was purged with dry nitrogen at a flow rate of 50 ml/min. The samples were evaluated 126 
according to DSC conditions (heating rate of 10 °C/min) during 3 cycles (heating, cooling and 127 
heating) from -20 to 200 °C. Crystallinity (%) was calculated with reference to the enthalpy of 128 
fusion (ΔHf*) of a perfect PVA crystal (138.6 J/g) (Mallapragada et al., 1997) with the following 129 
formula:  130 
            Xc= ( 
ࢤࡴࢌ
ࢤࡴࢌ∗ ) x 100  131 
All results were analysed in triplicate using the TA instrument Universal Analysis 2000 132 
software. A one-way analysis of variance (ANOVA) was performed with SPSS Statistics 133 
23 (IBM, New York, United States) to detect significant differences in Tg or Tm during 134 
extrusion, cryomilling and tableting of both PVA-grades. Tukey analysis was used to 135 
determine differences in Tg and Tm between extrusion, cryomilling and tableting. 136 
2.4.2. X-ray diffraction  137 
The crystallinity of PVA, sorbitol and CEL was investigated by means of X-ray diffraction. The 138 
X-ray diffraction patterns were determined using a D5000 Cu Kα diffractor (λ = 0.154 nm) 139 
(Siemens, Karlsruhe, Germany) with a voltage of 40 V in the angular range of 10° < 2θ < 60° 140 
using a step scan mode (step width = 0.02°, counting time = 1s/step).  141 
2.4.3. Solid-state 1H-NMR  142 
Solid-state 1H-wideline NMR measurements were carried out at ambient temperature on a 143 
Varian Inova 400 spectrometer in a dedicated wide-line probe equipped with a 5 mm coil using 144 
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the solid echo method (Mens et al., 2008). The samples were placed in 5 mm glass tubes, 145 
which were closed tightly with Teflon stoppers.  146 
The T1H relaxation decay times (spin-lattice relaxation in the lab frame) were measured by 147 
placing an inversion recovery filter in front of the solid echo part (180°x’ - t - 90°x’ - tse  - 90°y’ - 148 
tse - acquire). The length of the 90° pulse (t90) was set to 1.6 µs and spectra were recorded with 149 
a spectral width of 2 MHz (0.5 s dwell time), allowing an accurate determination of the echo 150 
maximum which is formed at  = (3t90/2 + 2tse) = 7 µs and this time point is calibrated to time 151 
zero. The integrated proton signal intensity was analyzed mono- or bi-exponentially as a 152 
function of the variable inversion time t according to: 153 
ܫሺݐሻ ൌ 	 ܫ଴ௌ ቀ1 െ 2 exp ቀെ ݐ ܶଵுೄൗ ቁቁ ൅	ܫ଴
௅ ቀ1 െ 2 exp ቀെ ݐ ܶଵுಽൗ ቁቁ ൅	ܥ
௦௧௘ 154 
‘S’ and ‘L’ refer to the fractions with short and long decay time, respectively.  155 
All experimental data were analyzed using a non-linear least-squares fit (Levenberg-Marquardt 156 
algorithm). A preparation delay of 5 times the longest T1H relaxation decay time was always 157 
respected between successive accumulations to obtain quantitative results. 158 
2.4.4. Particle size distribution 159 
Particle size distribution (PSD) of the powders was measured by laser diffraction (Mastersizer-160 
S long bench, Malvern Instruments, Malvern, UK). The measurements were done via dry 161 
dispersion method in volumetrical distribution mode using a 300 RF lens combined with a dry 162 
powder feeder (Malvern Instruments, Malvern, UK) at a feeding rate of 3.0 G and a jet pressure 163 
of 2.0 Bar. Measurements were performed in triplicate.  164 
2.4.5. Dynamic vapour sorption 165 
Dynamic vapour sorption (DVS Advantage, Surface Measurement Systems, Middlesex, UK) 166 
was used to assess the overall hygroscopicity of the materials. Approximately 10-20 mg of 167 
sample was placed into the instrument microbalance where it was dried under a stream of dry 168 
nitrogen at 25°C until equilibrium (i.e. a weight change of less than 0.002 % per minute during 169 
at least 15 min). The samples were subsequently exposed to various relative humidities (RH) 170 
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at 25°C, increasing from 0 to 80 % in steps of 20 %, from 80 to 90 % and from 90 to 98 % 171 
allowing equilibration at each interval.  172 
2.5. Tablet Evaluation  173 
Tablet evaluations were performed onto ten tablets. 174 
 175 
2.5.1. Tensile strength, breaking force and dimensions 176 
Tablet breaking force, diameter and thickness were determined using a hardness tester (Type 177 
HT10, Sotax, Basel, Switzerland). Tablet diametral tensile strength of the tablets (MPa) was 178 
derived using the following equation of Fell and Newton (1968): 179 
Tablet Tensile Strength (σt) = 
ଶ௉
గ஽௧ 180 
where P, D and t denote the diametral breaking force (N), tablet diameter (mm) and tablet 181 
thickness (mm), respectively. This formula can be used for double-convex cylindrical tablets 182 
as was reported by Podczeck et al. (Podczeck et al., 2013).  183 
2.5.2. Tablet porosity 184 
The porosity of the formed compacts was calculated using the following equation:    185 
Tablet Porosity = 1 െ	 	ఘೌ೛೛	ఘ೟ೝೠ೐  186 
where ρapp and ρtrue denote the apparent and true density (g/ml), respectively. Apparent 187 
density was calculated by dividing the tablet mass by the volume of the tablet, while the true 188 
density of all powders was measured using helium pycnometry (AccuPyc 1330, Micrometrics, 189 
Norcross, U.S.A) at an equilibration rate of 0.0050 psig/min with the number of purges set to 190 
10. 191 
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2.5.3 Tablet compaction characterization  192 
Compacts were prepared at different compaction pressures (100 to 400 MPa with a pre-193 
compression of 17 MPa), and tableting behaviour (tabletability, compressibility and 194 
compactibility) was evaluated. 195 
Tabletability was analysed by plotting tablet tensile strength to the compaction pressure. 196 
Compressibility was analysed by assessment of the tablet volume reduction (tablet porosity 197 
normalised by compaction pressure). Compactibility of pharmaceutical powders is generally 198 
described by use of the Ryshkewitch equation: 199 
     	ߪ௧ ൌ 	ߪ଴	݁ି௕௉                      200 
where σt and ߪ଴ denotes the tablet tensile strength (MPa) and limiting tablet tensile strength 201 
at zero porosity (MPa), respectively, b is an empirical constant and P denotes the tablet 202 
porosity (Ryshkewitch, 1953).  203 
2.5.4. Axial recovery 204 
Axial recovery of the tablets immediately after ejection (IAR) was calculated by use of the 205 
Armstrong and Haines-Nutt equation (Armstrong and Haines-Nutt, 1972):  206 
                     ܫܣܴ	ሺ%ሻ ൌ ቀ	்ೌ ି	்೔೏்೔೏ ቁ ݔ100 207 
where Ta denotes the tablet height immediately after ejection (mm) and Tid the tablet height 208 
under maximum compression force at main compression (mm). The dimensions of 10 tablets, 209 
manufactured at equal conditions, were used to calculate the % IAR of each formulation at 4 210 
compaction pressures.   211 
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3. RESULTS AND DISCUSSION 212 
3.1. Characterization  213 
Thermal stability of PVA505 and PVA4-88 was evaluated by means of thermogravimetric 214 
analysis (TGA) (data not shown). This technique showed an onset of thermal polymer 215 
degradation at 240°C, which indicated that PVA polymers are stable under the process 216 
conditions used in this study (maximum extrusion temperature of 180°C was used) 217 
(Alexy et al., 2004; De Jaeghere et al., 2015; Peng and Kong, 2007). 218 
Previous research work already showed the ability of sorbitol to act as low molecular weight 219 
plasticizer of PVA. Therefore, melting of PVA-sorbitol mixtures was required to establish 220 
molecular interactions between polymer and sorbitol, as no effect of sorbitol was observed 221 
during 1st DSC heating cycle. The plasticizing effect of sorbitol was linked to its concentration 222 
as more interactions can be established between the OH-groups of both components, thus 223 
disrupting the structural regularity of PVA (De Jaeghere et al., 2015). DSC analysis was used 224 
to examine the influence of extrusion, cryo-milling and tableting on the physicochemical 225 
properties of PVA and sorbitol. Tg of sorbitol was lower in the cryo-milled extrudates due to 226 
their higher water content (an increase of 1-1.5% was observed compared to HME samples): 227 
after HME and cryo-milling Tg was -8.1±0.3°C and -15.5±0.1°C, respectively, for PVA505 and -228 
3.6±0.2°C and -14.5±1.6°C, respectively, for PVA4-88. ANOVA showed no significant 229 
difference (p > 0.05) in Tg of both PVA-grades during extrusion, cryo-milling and 230 
tableting, however significant difference (p < 0.05) was observed in Tm of both PVA-231 
grades, which was slightly increased during processing (Table 1).  232 
DSC analysis showed endothermic peaks between 60-75°C and after 1 week X-ray diffraction 233 
patterns showed some degree of crystallinity in the samples (Fig.1). This phenomena was 234 
linked to the crystallization of sorbitol polymorphs during storage (Nezzal et al., 2009; Sztatisz 235 
et al., 1977). Due to this (re)-crystallization of sorbitol, the plasticizing effect of sorbitol was 236 
reduced and Tm of PVA slightly increased. Furthermore, solid-state 1H-wideline NMR (Table 2) 237 
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was performed, whereby a short relaxation decay time of 6.3s was found for semi-crystalline 238 
PVA4-88, and a long relaxation decay time of 26.3s for crystalline sorbitol. After extrusion, PVA4-239 
88 and sorbitol interacted with each other, as both fractions (I0S and I0L) were changed compared 240 
to the physical mixtures and the relaxation decay times of PVA4-88 and sorbitol were decreased. 241 
However, phase separation was observed for extrudates containing 40% sorbitol, as 242 
evidenced by the presence of 2 relaxation decay times. Therefore, experiments were repeated 243 
with extrudates containing less sorbitol (i.e. 10%), whereby only one relaxation decay time of 244 
14.2s was observed, which could mean that sorbitol was homogenized with PVA4-88 and more 245 
stable inside the extrudates. This result was linked to the DSC results whereas no re-246 
crystallization of sorbitol was observed. 247 
PSD of both PVA-grades and sorbitol were measured by means of laser diffraction (Table 3). 248 
Although all powders were sieved to a fraction smaller than 300 micron, d90 –values exceeded 249 
300 micron for all samples as there was a tendency for the material to agglomerate during the 250 
measurements. Fine powders are more subjected to agglomeration since their small particle 251 
size increases surface-mass ratio, which favours the bonding (Parikh, 2010). 252 
DVS was used to calculate moisture sorption and desorption isotherms in order to assess the 253 
hygroscopic behavior of the PVA-sorbitol mixtures (physical mixtures and cryo-milled 254 
extrudates) (Fig.2). The influence of sorbitol was clearly visible at extreme conditions 255 
(21°C/98%RH) as non-extruded PVA (A) had a water content of 30 %, which increased up to 256 
80% by addition of sorbitol (C). This was expected from the sorption isotherms of crystalline 257 
sorbitol (data not shown) which revealed water contents >80% at equal conditions. The level 258 
of hysteresis was negligible for pure PVA before and after extrusion (A,B) which could be 259 
attributed to intermolecular hydrogen bondings between the polymer chains (Assender and 260 
Windle, 1998), whereby the hydroxyl groups of PVA are not available for binding with water 261 
molecules. Interestingly, when comparing PVA-sorbitol (60:40) before and after extrusion (C,D) 262 
there was a remarkable difference in the level of hysteresis. While for the non-extruded 263 
formulation hysteresis was clearly present, it became negligible for the extruded formulation. 264 
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This was explained by DSC data which showed that interactions between PVA and sorbitol 265 
only occurred when sorbitol was melted by HME (De Jaeghere et al., 2015). The resulting 266 
extrudates are dense particles (Page and Maurer, 2014). It has been described in literature 267 
that for amorphous sugars the packing of molecules affected the water sorption behaviour. In 268 
dense glassy particles, adsorption of water occurs mainly on the surfaces (weak interactions) 269 
because of the absence of pores penetrable to water (Jouppila, 2006).  270 
This is applicable for the PVA-sorbitol extrudates, since DSC results revealed that amorphous 271 
sorbitol clusters are present in the PVA carrier (separate Tg for sorbitol and PVA). The moisture 272 
content of all formulations was lower (< 5 %) at laboratory conditions (35-60 % RH).  273 
3.2. Tablet properties  274 
3.2.1. Tabletability  275 
Tabletability describes the relationship between tensile strength of a tablet and compaction 276 
pressure exerted on these tablets (Fig.3) (Joiris et al., 1998). A strong increase of tablet 277 
strength was observed at low compaction pressures for most mixtures, however the curves 278 
leveled off at higher compaction pressures. This was explained by the phenomenon of elastic 279 
recovery, which occurred after removal of the compaction load (i.e. decompression).  280 
As powders are compressed, particles come in closer contact by volume reduction 281 
mechanisms (particle rearrangements, fragmentation, plastic/elastic deformation), which 282 
reduced tablet porosity. This leads to a steep increase in the bonding area and consequently 283 
in tensile strength of the tablets (Duberg and Nyström, 1986). In the low-pressure region, 284 
elastic recovery of the tablet after compression was negligible and the tablet strength increased 285 
linear with the compaction pressure. At higher compaction pressures, tablet porosity was 286 
already reduced considerably so further increase of the compaction pressure led to elastic 287 
deformation rather than a further decrease in porosity (Sun and Grant, 2001). Inevitable, such 288 
particles store elastic energy, which is linked to a certain elastic recovery at decompression, 289 
thereby reducing the bonding area. The associated reduced points of contact between 290 
  13
neighbouring particles in the tablet caused a level off in tensile strength (Sun, 2011). In general, 291 
tabletability curves of the extrudates were lower than those of the physical mixtures and the 292 
increase in tablet strength was limited (i.e. level off at lower compaction pressures). These 293 
results were in line with earlier findings on the tabletability of HME materials (Agrawal et al., 294 
2013; Boersen et al., 2013). While the tensile strength of physical mixtures increased in 295 
function of the concentration of crystalline sorbitol (a value of 2.5 MPa was recorded for 40 % 296 
sorbitol at a compaction pressure of 300 MPa), the tensile strength of extruded samples was 297 
lower at higher amorphous sorbitol content (at 40 % sorbitol content the tablets manufactured 298 
at various compaction pressures were even too soft for measuring the diametrical breaking 299 
force) (Fig. 3, A). In addition, maximum tabletability (i.e. highest tensile strength) was obtained 300 
at lower compaction pressures for extrudates compared to physical mixtures, at about 200 301 
MPa and > 400 MPa, respectively (Fig.3, B). Differences in particle size (Table 2) could explain 302 
the lower position of the curves but could not explain the limited increase in tablet strength and 303 
the early level off at lower compaction pressures. Agrawal et al. attributed this to the possible 304 
weaker interactions between glassy materials resulting in tablets with lower tensile strengths 305 
(Agrawal et al., 2013). In this study it was hypothesized that the process of HME altered the 306 
mechanical properties of the PVA-sorbitol-carrier and therefore changed its volume reduction 307 
mechanism towards a more elastically deforming material. Iyer et al. reported an increase in 308 
the elasticity of melt-extruded HPMC-AS and linked this with a likely higher elastic recovery 309 
after compression (Iyer et al., 2013). It is possible that the HME-process induced a similar 310 
change in the elastic deformation of PVA-sorbitol, leading to higher elastic recoveries with 311 
increasing amorphous fraction (Fig.1: the absence of sharp crystalline peaks in the XRD-data 312 
of cryo-milled extrudates compared to the physical mixtures). Boersen et al. reported similar 313 
findings, where brittle fracture index experiments showed a reduction in the plasticity of HME-314 
powders (Boersen et al., 2013).  315 
Comparison of figures A and B indicated that physical mixtures of non-extruded PVA4-88 yielded 316 
tablets of higher tensile strengths than physical mixtures of PVA505 at equal compaction 317 
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pressures (an increase of 80 % in tensile strength was recorded at a compaction pressure of 318 
300 MPa). This was explained by the differences in crystalline content of both polymers, since 319 
PVA is a semi-crystalline polymer (Agrawal et al., 2013). The crystalline content of pure PVA4-320 
88 (32.1%) was significantly higher compared to pure PVA505 (16.6%), which resulted in 321 
‘stronger’ tablets, and HME reduced the crystallinity of PVA4-88 significantly (21.4%) compared 322 
to PVA505 (14.4%) as the higher extrusion temperatures disrupted inter- and intramolecular 323 
hydrogen bonding. Additionally, differences in PSD of the physical mixtures (Table 2) also 324 
contributed to this phenomenon.  325 
Tabletability on its own does not provide a fundamental understanding of the tableting 326 
behaviour of pharmaceutical powders, since bonding area (reflected by compressibility) and 327 
bonding strength per unit bonding area (reflected by compactibility) also determine the tensile 328 
strength of tablets. Only by simultaneously analysing particle size, compressibility, 329 
compactibility and tabletability, an extensive insight in the tablet properties can be obtained 330 
(Sun and Grant, 2001). 331 
3.2.2. Compressibility  332 
Compressibility of a material is its ability to be reduced in volume as a result of an applied 333 
pressure (Joiris et al., 1998). The compressibility profiles showed similar trends as tabletability, 334 
with physical mixtures having greater compressibility (i.e. yielding lower tablet porosities) 335 
compared to the extrudates (Fig. 4). While the lowest tablet porosities were observed for 336 
physical mixtures with higher content of crystalline sorbitol, porosities increased in extrudates 337 
with more amorphous content (i.e. high sorbitol content). In addition, maximum compressibility 338 
(i.e. lowest tablet porosity) was obtained at a lower compaction pressures for extrudates 339 
containing (amorphous) sorbitol compared to physical mixtures, at about 250 MPa and >400 340 
MPa, respectively (Fig. 4). The differences between physical mixtures and extrudates were 341 
linked to HME. A higher amorphous content in the extrudates induced an early level off in the 342 
compressibility profiles, resulting in constant tablet porosity at higher compaction pressures 343 
because of the effect of elastic recovery (Fig. 4). These results were in line with tabletability 344 
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profiles where an early flattening was observed in tablet tensile strength of the extrudates. 345 
Therefore, the assumption of a altered volume reduction mechanism due to hot-melt extrusion 346 
was strengthened. If HME altered the mechanical properties of PVA-sorbitol towards a more 347 
elastical deforming material, the stored elastic energy increased in function of the applied 348 
external force and hence resulted in more elastic recovery of the tablets during decompression 349 
(Sun and Grant, 2001). Therefore, the reduced porosity due elastic deformation was 350 
counteracted by the elastic recovery causing a level off in the curve. 351 
By comparing tablet porosities at equal compaction pressures for physical mixtures of PVA505 352 
and PVA4-88, it was clear that particle size had a strong influence. Lower tablet porosities were 353 
detected with PVA4-88 –mixtures (tablet porosity was 0.14 and 0.08 for physical mixtures with 354 
PVA4-88 and PVA505, respectively), since these had smaller particle sizes (Table 2). However, 355 
the effect of extrusion on the pure polymers was clearly visible. While for PVA505 the curves of 356 
physical mixtures and extrudates are superimposed (Fig.4,A), this is not the case for PVA4-88 357 
since higher tablet porosities were reached for the extrudates of PVA4-88 (Fig.4,B). This was 358 
explained by the differences in crystalline content of both polymers. Extrusion of pure PVA4-88 359 
increased the amorphous fraction of the semi-crystalline polymer, which favoured elastic 360 
deformation and hence increased the elastic recovery. This was not the case for pure PVA505, 361 
since the crystalline content did not changed remarkably.  362 
3.2.3. Compactibility  363 
Compactibility describes the relationship between tensile strength and porosity (Fig.5). Tablet 364 
tensile strength decreased exponentially with increasing porosities, as described by the 365 
Ryshkewitch equation (Ryshkewitch, 1953). Although physical mixtures and extrudates 366 
showed large differences in tabletability (i.e. tensile strengths), these differences were less 367 
distinct when tablet tensile strength was plotted at zero porosity, especially for PVA505.  368 
Since compactibility can be used to quantify bonding strength between particles at zero 369 
porosity (Joiris et al., 1998; Maarschalk et al., 1996; Sun, 2011), these results suggested that 370 
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the higher tensile strength was more related to the interparticulate bonding area (i.e. 371 
compressibility) compared to the bonding strength per unit bonding area (i.e. compactibility). 372 
However, compactibility curves of both PVA-types gave evidence of weaker interactions 373 
between glassy materials (Agrawal et al., 2013) since compression of physical mixtures with 374 
increasing sorbitol content (i.e. higher crystalline fraction) resulted in a higher tensile strength 375 
at zero porosities. This effect was clearly reflected in the lower position of the compactibility 376 
curve of pure PVA4-88 extrudates compared to the physical mixture (Fig.5, B), which was linked 377 
to the lower crystalline content of the semi-crystalline polymer after HME. This effect was not 378 
significant for PVA505 and therefore those curves (PM vs. EX) were almost superimposed at 379 
zero porosity (Fig.5,A), indicating that almost no changes in bonding strength occurred. In 380 
general, this study revealed that differences in tablet tensile strength for PVA-sorbitol carriers 381 
were the result of altered interparticulate bonding areas (elastic recovery and particle size) 382 
combined with a change in the bonding strengths for glassy materials (Agrawal et al., 2013) 383 
after extrusion.  384 
3.2.4. Axial recovery  385 
Axial recovery of the tablets calculated immediately after tablet ejection (IAR) was selected as 386 
the “out-of-die” recovery descriptor. For each formulation, IAR was calculated for tablets of 387 
non-extruded physical mixtures and extruded mixtures at 4 compaction pressures. The results 388 
are shown in Fig.6 as a ratio of the IAR before and after extrusion in function of the compaction 389 
pressure.  390 
All calculated ratios were higher or equal to the value 1 indicating that tablets of extruded 391 
powders experienced higher or equal IAR compared to tablets of their physical mixtures (i.e. 392 
not subjected to HME). Only for pure PVA505, HME had no impact on the IAR-ratio of the tablets 393 
(ratio = 1), as no change in crystalline content of pure PVA505-polymer was observed after HME. 394 
However, IAR-ratios of pure PVA4-88 were > 1 since HME affected the amorphous content of 395 
the polymer. The addition of sorbitol to the formulations, which changed from crystalline to 396 
amorphous state after HME, resulted in higher %IAR ratios of the tablets. These results 397 
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showed that the higher amorphous content of formulations due to HME was reflected in the 398 
IAR of the tablets. Additionally, these results were in line with the CTC-profiles and confirmed 399 
the hypothesis that due to HME, materials were transformed towards a more amorphous state, 400 
hereby experiencing more elastic deformation during compression.   401 
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4. CONCLUSIONS 402 
This study demonstrated that HME could alter the mechanical properties of PVA-sorbitol 403 
carriers, thereby negatively affecting the tableting behaviour (i.e. lowering tablet tensile 404 
strength) with increasing amorphous content. This resulted from a combined effect of less 405 
interparticulate bonding areas (because of higher elastic recoveries) and weaker bonding 406 
strengths per unit bonding area (i.e. lower tensile strengths at zero porosity).  In general, it can 407 
be concluded that it will be necessary to further optimize the formulation (e.g. plasticizer 408 
content) in order to improve the tableting behaviour of PVA-sorbitol extrudates.  409 
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Figure 1: XRD profiles (left) of sorbitol (A), physical mixture PVA-sorbitol (60:40) (B), cryom. extrudate (C) and  506 
cryom. extrudate after 1 week (D). DSC profiles (right) of extrudate (EX) and cryom. extrudate after at time point 0 507 
and after 1 week. 508 
Figure 2: DVS sorption (_) and desorption (…) curves of PVA4-88 (A) , PVA4-88 cryomilled extrudate (B), PVA4-88-509 
sorbitol (60:40) physical mixture (C), PVA4-88-sorbitol (60:40) cryomilled extrudate (D) and sorbitol (E) at 21 °C.  510 
Figure 3: Tabletability of physical mixtures (PM) and hot-melt extruded (EX) samples formulated with PVA505 (A) 511 
or PVA4-88 (B),, in combination with 0, 10 or 40% sorbitol (n=10).  512 
Figure 4: Compressibility  of physical mixtures (PM) and hot-melt extruded (EX) samples formulated with PVA505 513 
(A) and PVA4-88 (B), in combination with 0, 10 or 40% sorbitol (n=10).  514 
Figure 5: Compactibility  of physical mixtures (PM) and hot-melt extruded (EX) samples formulated with PVA505 (A) 515 
or PVA4-88 (B), in combination with 0, 10 or 40% sorbitol (n=10). 516 
Figure 6: IAR-ratio of physical mixtures (PM) and hot-melt extruded samples (EX) at various compaction pressures 517 
for formulations containing PVA and sorbitol  (n=10).  518 
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Figure 2: DVS sorption (_) and desorption (…) curves of PVA4-88 (A) , PVA4-88 cryomilled 527 
extrudate (B), PVA4-88-sorbitol (60:40) physical mixture (C), PVA4-88-sorbitol (60:40) 528 
cryomilled extrudate (D) and sorbitol (E) at 21 °C.  529 
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Figure 3: Tabletability of physical mixtures (PM) and hot-melt extruded (EX) samples formulated with PVA505 (A) 535 
or PVA4-88 (B),, in combination with 0, 10 or 40% sorbitol (n=10). 536 
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Figure 4: Compressibility of physical mixtures (PM) and hot-melt extruded (EX) samples formulated with PVA505 555 
(A) and PVA4-88 (B), in combination with 0, 10 or 40% sorbitol (n=10). 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
 573 
 574 
 575 
 576 
 577 
 578 
   579 
  27
Figure 5: Compactibility of physical mixtures (PM) and hot-melt extruded (EX) samples formulated with PVA505 (A) 580 
or PVA4-88 (B), in combination with 0, 10 or 40% sorbitol (n=10). 581 
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Figure 6: IAR-ratio of physical mixtures (PM) and hot-melt extruded samples (EX) at various 599 
compaction pressures for formulations containing PVA and sorbitol  (n=10).  600 
 601 
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 610 
 611 
  612 
  29
Table 1: Thermal properties of unplasticized and plasticized (containing 40% sorbitol) PVA after extrusion, cryo-613 
milling and tableting using a heating rate of 10°C/min. The significance of the results was determined with ANOVA. 614 
Means of Tg (a,b) or Tm (c,d) in the same column with different superscripts are different at the 0.05 level of significance 615 
(Tukey) (n = 3). 616 
Table 2: Solid-state 1H-wideline NMR relaxation decay times (T1H) and fractions (IO) of PVA4-88, sorbitol, physical 617 
mixtures and extrudates containing 40% and 10% sorbitol 618 
Table 3: Mean particle size distribution of physical mixtures (PM) and cryo-milled extrudates (EX) of PVA/sorbitol 619 
formulations, measured via dry laser diffraction (n=3).  620 
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Table 1: Thermal properties of unplasticized and plasticized (containing 40% sorbitol) PVA after extrusion, cryo-644 
milling and tableting using a heating rate of 10°C/min. The significance of the results was determined with ANOVA. 645 
Means of Tg (a,b) or Tm (c,d) in the same column with different superscripts are different at the 0.05 level of significance 646 
(Tukey) (n = 3). 647 
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EXTRUSION	 Tg (°C) 34.3 ±3.2
a	 38.6	±1.1a	
Tm	(ons.)	(°C) 117.7 ±2.4c	 133.1	±4.7c	
	 	 	 	
CRYOMILLING	 Tg (°C) 30.5 ±2.5
a	 37.9	±3.4a	
Tm	(ons.)	(°C) 121.8 ±5.2c	 149.1	±3.3d	
	 	 	 	
TABLETING	 Tg (°C) 31.6 ±1.5
a	 38.2	±5.0a	
Tm	(ons.)	(°C) 131.2 ±3.8d	 149.1	±2.2d	
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Table 2: Solid-state 1H-wideline NMR relaxation decay times (T1H) and fractions (IO) of PVA4-88, sorbitol, physical 658 
mixtures (PM) and extrudates (EX) containing 40% and 10% sorbitol 659 
 660 
SAMPLE  T1H (s) T1HS     IoS (%)        T1HL      IoL (%)     
PVA4‐88  6.3  100.0     
Sorbitol      26.3  100.0 
PVA4‐88‐Sorbitol (60:40) PM  6.0  63.4  25.4  36.6 
PVA4‐88‐Sorbitol (60:40) EX  3.5  88.0  15.7  12.0 
PVA4‐88‐Sorbitol (90:10) EX      14.2  100.0 
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Table 3: Mean particle size distribution of physical mixtures (PM) and cryo-milled extrudates (EX) of PVA/sorbitol 681 
formulations, measured via dry laser diffraction (n=3).  682 
 683 
  d10
(μm) 
d50
(μm) 
d90
(μm) 
PVA505 
 
PM 
  EX 
47.6 ±5.96
68.8 ±0.07 
204.3 ±4.74
187.6 ±0.69 
  404.1 ±32.98
359.1 ±6.39 
PVA4‐88 
 
PM 
  EX 
22.9 ±0.52
73.4 ±4.43 
 164.4 ±16.71
203.0 ±5.78 
544.0 ±7.41
367.2 ±4.15 
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